Drug treatment of metabolic syndrome

Current Clinical Pharmacology

Volumn 8, Issue 3, 2013, Pages 224-231

  Altabas, Velimir ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Metabolic syndrome; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; METFORMIN; MOXONIDINE; OMEGA 3 FATTY ACID; RENIN INHIBITOR; SIMVASTATIN; TETRAHYDROLIPSTATIN;

ABDOMINAL DISCOMFORT; ARTICLE; CARDIOVASCULAR DISEASE; DIARRHEA; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FLATULENCE; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LIVER FAILURE; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; STEATORRHEA;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIFE STYLE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; RISK FACTORS;

EID: 84882799486     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308030009     Document Type: Article

References (96)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1600.
2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49(4): 403-14.
3. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56(14): 1113-32.
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539-53.
5. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421.
7. Reaven P. Metabolic syndrome. J Insur Med 2004; 36(2): 132-42.
8. Reaven GM. Is diagnosing metabolic syndrome a uniquely simple way to predict incident type 2 diabetes mellitus? CMAJ 2009; 180(6): 601-2.
9. Mertens I, Van Gaal LF. New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thromb Haemost 2006; 4(5): 1164-6.
10. Parish JM, Adam T, Facchiano L. Relationship of metabolic syndrome and obstructive sleep apnea. J Clin Sleep Med 2007; 3(5): 467-72.
11. Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SI. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med 2008; 4(3): 261-72.
12. Garruti G, Depalo R, Vita MG, et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online 2009; 19(4): 552-63.
13. Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 2007; 50(1): 205-25.
14. Panza F, Frisardi V, Seripa D, et al. Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res 2011; 8(5): 492-509.
15. Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol Aging 2011; 32(11): 1932-41.
16. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey 1988-1994. Arch Intern Med 2003; 163(4): 427-36.
17. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33(2): 283-303.
18. Poulsen P, Vaag A, Kyvik K, Beck-Nielsen H. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia 2001; 44(5): 537-43.
19. Sale MM, Woods J, Freedman BI. Genetic determinants of the metabolic syndrome. Curr Hypertens Rep 2006; 8(1): 16-22.
20. Andreassi MG. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction. Mutat Res 2009; 667(1-2): 35-43.
21. Sharma V, McNeill JH. The etiology of hypertension in the metabolic syndrome part two: the gene-environment interaction. Curr Vasc Pharmacol 2006; 4(4): 305-20.
22. Poulsen P, Vaag A. The impact of genes and preand postnatal environment on the metabolic syndrome. Evidence from twin studies. Panminerva Med 2003; 45(2): 109-15.
23. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005; 149(1): 33-45.
24. Balkau B, Vierron E, Vernay M, et al. The impact of 3-year changes in lifestyle habits on metabolic syndrome parameters: the D.E.S.I.R study. Eur J Cardiovasc Prev Rehabil 2006; 13(3): 334-40.
25. Wannamethee SG, Shaper AG, Whincup PH. Modifiable lifestyle factors and the metabolic syndrome in older men: Effects of lifestyle changes. J Am Geriatr Soc 2006; 54(12): 1909-14.
26. Miyatake N, Fujii M, Miyachi M, et al. Changes in metabolic syndrome and its components with lifestyle modification in Japanese men. Intern Med 2010; 49(4): 261-5.
27. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and longterm hypertension outcomes: a systematic review. Hypertension 2005; 45(6): 1035-41.
28. Moore LL, Visioni AJ, Qureshi MM, Bradlee ML, Ellison RC, D'Agostino R. Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med 2005; 165(11): 1298-303.
29. Kuller LH. Weight loss and reduction of blood pressure and hypertension. Hypertension 2009; 54(4): 700-1.
30. Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM. Lifestyle approaches and dietary strategies to lower LDLcholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am 2009; 38(1): 45-78.
31. Barter P. Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction. Atheroscler Suppl 2011; 12(3): 265-6.
32. Esposito K, Ceriello A, Giugliano D. Diet and the metabolic syndrome. Metab Syndr Relat Disord 2007; 5(4): 291-6.
33. Vernon MC, Kueser B, Transue M, Yates HE, Yancy WS, Westman EC. Clinical experience of a carbohydrate-restricted diet for the metabolic syndrome. Metab Syndr Relat Disord 2004; 2(3): 180-6.
34. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006; 66(12): 1625-56.
35. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, overthecounter dosage. Expert Opin Pharmacother 2007; 8(11): 1733-42.
36. Sternby B, Hartmann D, Borgstrom B, Nilsson A. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine. Clin Nutr 2002; 21(5): 395-402.
37. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9(2): 160-7.
38. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5(1): 51-68.
39. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8(1): 49-61.
40. Sjostrom L. Analysis of the XENDOS study (Xenical in the Prevention of Diabetes in Obese Subjects). Endocr Pract 2006; 12(Suppl 1): 31-3.
41. Siebenhofer A, Horvath K, Jeitler K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009(3): CD007654.
42. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulintreated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25(6): 1033-41.
43. Thurairajah PH, Syn WK, Neil DA, Stell D, Haydon G. Orlistat (Xenical)-induced subacute liver failure. Eur J Gastroenterol Hepatol 2005; 17(12): 1437-8.
44. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-72.
45. Gandhi GY, Isley WL. Review: ACE inhibitors and angiotensinreceptor blockers reduce diabetes in hypertension and other CV risk factors. ACP J Club 2007; 146(1): 11.
46. McFarlane PA. Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy. Evid Based Med 2006; 11(5): 144.
47. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens Suppl 2006; 24(1): S73-80.
48. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120(14): 1380-9.
49. Ruggenenti P, Iliev I, Costa GM, et al. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 2008; 31(8): 1629-34.
50. Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM, Krieger JE. ACE gene dosage modulates pressure-induced cardiac hypertrophy in mice and men. Physiol Genomics 2006; 27(3): 237-44.
51. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004; 20(10): 1559-69.
52. Matsukawa T, Miyamoto T. Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol 2010; 300(3): R624-9.
53. Ruggenenti P, Fassi A, Ilieva AP, et al. Effects of verapamil addedon trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens 2005; 29(2): 207-16.
54. Landray MJ. Sudden death: ACE inhibitors and beta-blockers. Basic Res Cardiol 2000; 95 Suppl 1: I37-40.
55. Carides GW, Shahinfar S, Dasbach EJ, et al. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics 2006; 24(6): 549-58.
56. Hunsicker LG, Atkins RC, Lewis JB, et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004(92): S99-101.
57. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64(9): 999-1028.
58. Smink PA, Bakker SJ, Laverman GD, et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J Hypertens 2012; 30(5):1022-8.
59. Mogi M, Horiuchi M. Effects of angiotensin II receptor blockers on dementia. Hypertens Res 2009; 32(9): 738-40.
60. Ueshiba H, Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003; 35(9): 532-6.
61. Courtney CH, McCance DR, Atkinson AB, et al. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism 2003; 52(9): 1147-52.
62. Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 2000; 355(9207): 863-4.
63. Gavras I, Gavras H. Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? Curr Control Trials Cardiovasc Med 2001; 2(6): 257-259.
64. Sun Z, Ernsberger P. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. J Pharmacol Exp Ther 2007; 320(2): 845-52.
65. Abellan J, Leal M, Hernandez-Menarguez F, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005(93): S20-4.
66. Messerli F. Moxonidine: a new and versatile antihypertensive. J Cardiovasc Pharmacol 2000; 35(7 Suppl 4): S53-6.
67. Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab 2006; 8(4): 456-65.
68. Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6(5): 343-8.
69. Kirmizis D, Chatzidimitriou D. Pleiotropic vasoprotective effects of statins: the chicken or the egg? Drug Des Devel Ther 2009; 3: 191-204.
70. Sontheimer D. Review: statins reduce all-cause mortality in elderly patients with coronary heart disease. ACP J Club 2008; 148(3): 3.
71. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8(5): 453-63.
72. McAlister FA. ACP Journal Club. Review: Statins are effective for prevention of cardiovascular events in patients without coronary heart disease. Ann Intern Med 2009; 150(8): JC4-5.
73. Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol 2009; 104(12): 1689-94.
74. Forbes K, Hurst LM, Aplin JD, Westwood M, Gibson JM. Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable. J Cell Mol Med 2008; 12(6A): 2295-6.
75. Vittone F, Chait A, Morse JS, Fish B, Brown BG, Zhao XQ. Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 2007; 1(3): 203-210.
76. Virani SS, Ballantyne CM. Therapy and clinical trials: HDLcholesterol and niacin therapy--past, present, and future. Curr Opin Lipidol 2010; 21(2): 165-6.
77. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008; 83(4): 470-8.
78. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164(2): 361-9.
79. Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009; 24(4): 364-71.
80. Cannon CP, Dansky HM, Davidson M, et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 2009; 158(4): 513-519 e3.
81. Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009; 20(6): 505-11.
82. Verges B. Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol 2005; 16(6): 648-51.
83. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 2008; 102(8): 1040-5.
84. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl 1): 1-68.
85. Standards of medical care in diabetes--2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
86. Lehtovirta M, Forsen B, Gullstrom M, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med 2001; 18(7): 578-83.
87. Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009; 55(4): 363-9.
88. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374(9702): 1677-86.
89. Wan Q, Wang F, Guan Q, et al. Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial. Diabet Med 2010; 27(11): 1312-7.
90. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54(4): 1150-6.
91. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364(12): 1104-15.
92. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet 2002; 359(9323): 2072-7.
93. Blaha MJ, Bansal S, Rouf R, Golden SH, Blumenthal RS, Defilippis AP. A practical ABCDE approach to the metabolic syndrome. Mayo Clin Proc 2008; 83(8): 932-41.
94. Shields TM, Hennekens CH. Management of metabolic syndrome: aspirin. Endocrinol Metab Clin North Am 2004; 33(3): 577-93.
95. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
96. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150(6): 405-10.